Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 20 | 2020 | 543 | 1.630 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2017 | 236 | 0.950 |
Why?
|
| Thoracotomy | 4 | 2016 | 30 | 0.730 |
Why?
|
| Pneumonectomy | 5 | 2020 | 76 | 0.660 |
Why?
|
| Esophageal Neoplasms | 3 | 2015 | 50 | 0.570 |
Why?
|
| Thoracic Surgery, Video-Assisted | 3 | 2020 | 21 | 0.530 |
Why?
|
| Adenocarcinoma | 7 | 2015 | 135 | 0.530 |
Why?
|
| Unnecessary Procedures | 2 | 2019 | 27 | 0.500 |
Why?
|
| Biomarkers, Tumor | 5 | 2015 | 203 | 0.480 |
Why?
|
| Esophagectomy | 2 | 2011 | 23 | 0.450 |
Why?
|
| Barrett Esophagus | 4 | 2015 | 16 | 0.450 |
Why?
|
| Catheter Ablation | 4 | 2015 | 46 | 0.440 |
Why?
|
| Aged | 26 | 2019 | 8732 | 0.380 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 4 | 0.360 |
Why?
|
| Jejunostomy | 1 | 2011 | 8 | 0.360 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 62 | 0.350 |
Why?
|
| Abnormalities, Drug-Induced | 4 | 2016 | 7 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 206 | 0.330 |
Why?
|
| Male | 29 | 2019 | 14277 | 0.320 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 360 | 0.320 |
Why?
|
| Empyema, Pleural | 1 | 2009 | 1 | 0.310 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2009 | 4 | 0.310 |
Why?
|
| Female | 30 | 2019 | 14734 | 0.310 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 66 | 0.300 |
Why?
|
| Surgical Wound Infection | 1 | 2009 | 85 | 0.290 |
Why?
|
| Postoperative Complications | 4 | 2016 | 901 | 0.280 |
Why?
|
| Positron-Emission Tomography | 3 | 2011 | 84 | 0.280 |
Why?
|
| Echinocandins | 3 | 2012 | 6 | 0.280 |
Why?
|
| Drainage | 2 | 2009 | 41 | 0.270 |
Why?
|
| Toxicity Tests | 4 | 2016 | 9 | 0.270 |
Why?
|
| Humans | 32 | 2020 | 25967 | 0.250 |
Why?
|
| Middle Aged | 20 | 2017 | 8772 | 0.250 |
Why?
|
| Embryonic Development | 3 | 2016 | 7 | 0.250 |
Why?
|
| Retrospective Studies | 11 | 2017 | 3358 | 0.250 |
Why?
|
| Embryo, Mammalian | 2 | 2016 | 25 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 165 | 0.220 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2015 | 14 | 0.220 |
Why?
|
| Bronchoscopy | 3 | 2019 | 33 | 0.210 |
Why?
|
| Pleurodesis | 1 | 2003 | 1 | 0.200 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 4 | 0.200 |
Why?
|
| Prognosis | 6 | 2017 | 784 | 0.200 |
Why?
|
| Aged, 80 and over | 12 | 2017 | 4641 | 0.200 |
Why?
|
| Consensus | 2 | 2020 | 89 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2017 | 3399 | 0.190 |
Why?
|
| Radiosurgery | 3 | 2011 | 33 | 0.180 |
Why?
|
| Antifungal Agents | 2 | 2012 | 40 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2017 | 258 | 0.180 |
Why?
|
| Simulation Training | 1 | 2020 | 36 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 74 | 0.160 |
Why?
|
| Cohort Studies | 4 | 2017 | 1806 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2020 | 193 | 0.160 |
Why?
|
| Surgeons | 1 | 2020 | 84 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 7 | 0.160 |
Why?
|
| False Positive Reactions | 1 | 2019 | 33 | 0.150 |
Why?
|
| Fetal Development | 2 | 2016 | 3 | 0.150 |
Why?
|
| Registries | 4 | 2015 | 192 | 0.150 |
Why?
|
| Fetus | 2 | 2016 | 36 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 36 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2017 | 603 | 0.140 |
Why?
|
| Bone and Bones | 2 | 2016 | 117 | 0.140 |
Why?
|
| Length of Stay | 3 | 2016 | 307 | 0.140 |
Why?
|
| Clinical Competence | 2 | 2020 | 207 | 0.140 |
Why?
|
| Tracheomalacia | 1 | 2017 | 4 | 0.140 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 6 | 0.140 |
Why?
|
| Silicones | 1 | 2017 | 10 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 326 | 0.140 |
Why?
|
| Airway Obstruction | 1 | 2017 | 18 | 0.140 |
Why?
|
| Mutagenicity Tests | 1 | 2016 | 1 | 0.130 |
Why?
|
| Teratogens | 1 | 2016 | 1 | 0.130 |
Why?
|
| Hazardous Substances | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 8 | 0.130 |
Why?
|
| Stents | 1 | 2017 | 78 | 0.130 |
Why?
|
| Disease Progression | 4 | 2014 | 655 | 0.130 |
Why?
|
| Models, Animal | 1 | 2016 | 110 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 59 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 473 | 0.130 |
Why?
|
| Developmental Biology | 1 | 2016 | 1 | 0.130 |
Why?
|
| Ribs | 1 | 2016 | 12 | 0.130 |
Why?
|
| Thoracic Wall | 1 | 2016 | 12 | 0.120 |
Why?
|
| Metformin | 1 | 2016 | 16 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 36 | 0.120 |
Why?
|
| Animals | 8 | 2016 | 3503 | 0.120 |
Why?
|
| X-Ray Microtomography | 1 | 2016 | 78 | 0.120 |
Why?
|
| Rats | 5 | 2016 | 640 | 0.120 |
Why?
|
| Esophagoscopy | 1 | 2015 | 15 | 0.120 |
Why?
|
| Learning Curve | 1 | 2015 | 18 | 0.120 |
Why?
|
| Thoracoscopy | 2 | 2019 | 22 | 0.120 |
Why?
|
| Cytokines | 2 | 2014 | 225 | 0.120 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 10 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 10 | 0.110 |
Why?
|
| Tumor Burden | 3 | 2010 | 25 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 160 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 501 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 174 | 0.100 |
Why?
|
| Intubation, Intratracheal | 2 | 2016 | 87 | 0.100 |
Why?
|
| Research Design | 2 | 2012 | 183 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 11 | 0.100 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 11 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 466 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 337 | 0.100 |
Why?
|
| Fundoplication | 1 | 2012 | 22 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 37 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 27 | 0.100 |
Why?
|
| Adult | 8 | 2017 | 7662 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 648 | 0.100 |
Why?
|
| Nitriles | 1 | 2012 | 13 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 328 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2012 | 23 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 174 | 0.090 |
Why?
|
| Triazoles | 1 | 2012 | 29 | 0.090 |
Why?
|
| Fistula | 1 | 2011 | 2 | 0.090 |
Why?
|
| Gastric Fistula | 1 | 2011 | 5 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 7 | 0.090 |
Why?
|
| Nutrition Assessment | 1 | 2011 | 42 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2012 | 59 | 0.090 |
Why?
|
| Hospitals, Community | 1 | 2011 | 14 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 13 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2011 | 47 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 15 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2015 | 1701 | 0.090 |
Why?
|
| Algorithms | 3 | 2014 | 345 | 0.090 |
Why?
|
| Risk Factors | 5 | 2015 | 2237 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2011 | 44 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2011 | 61 | 0.090 |
Why?
|
| Minority Groups | 1 | 2011 | 71 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2010 | 18 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 21 | 0.080 |
Why?
|
| Bronchi | 1 | 2010 | 12 | 0.080 |
Why?
|
| Age Factors | 2 | 2009 | 757 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 210 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 190 | 0.080 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2009 | 9 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 174 | 0.080 |
Why?
|
| Trachea | 1 | 2010 | 39 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 87 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 117 | 0.080 |
Why?
|
| Thoracic Surgery | 1 | 2009 | 26 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2014 | 63 | 0.080 |
Why?
|
| Survival Rate | 2 | 2010 | 333 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 70 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 449 | 0.070 |
Why?
|
| United States | 4 | 2015 | 1989 | 0.070 |
Why?
|
| Recurrence | 2 | 2014 | 300 | 0.070 |
Why?
|
| Neoplasms | 1 | 2011 | 230 | 0.070 |
Why?
|
| Rats, Inbred F344 | 3 | 2012 | 34 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2009 | 185 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 157 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 91 | 0.070 |
Why?
|
| Time Factors | 3 | 2015 | 1391 | 0.060 |
Why?
|
| Rabbits | 2 | 2016 | 179 | 0.060 |
Why?
|
| Lung | 2 | 2005 | 157 | 0.060 |
Why?
|
| Pregnancy | 3 | 2012 | 327 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 302 | 0.060 |
Why?
|
| Pneumonia | 2 | 2019 | 70 | 0.060 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Logistic Models | 2 | 2015 | 391 | 0.060 |
Why?
|
| ROC Curve | 2 | 2014 | 141 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 1757 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 21 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 649 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 729 | 0.050 |
Why?
|
| Brain | 1 | 2011 | 1569 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 2 | 2012 | 11 | 0.050 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 454 | 0.040 |
Why?
|
| Reoperation | 2 | 2015 | 888 | 0.040 |
Why?
|
| Radiography | 2 | 2013 | 616 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 102 | 0.040 |
Why?
|
| Young Adult | 2 | 2014 | 1941 | 0.030 |
Why?
|
| Dilatation | 1 | 2017 | 10 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 16 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 8 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 13 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2016 | 21 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 97 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 56 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 16 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 23 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 337 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 137 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 90 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 64 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 332 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 121 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 6 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 544 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 268 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 240 | 0.030 |
Why?
|
| Illinois | 1 | 2014 | 235 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Granuloma | 1 | 2013 | 13 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 14 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2013 | 18 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 24 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 74 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2012 | 1 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 45 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 88 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 21 | 0.020 |
Why?
|
| Voriconazole | 1 | 2012 | 10 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 34 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 33 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 30 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 42 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2012 | 29 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 181 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 104 | 0.020 |
Why?
|
| Hematemesis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 132 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 4 | 0.020 |
Why?
|
| Esophageal Perforation | 1 | 2011 | 8 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 55 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 22 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2012 | 82 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 104 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 23 | 0.020 |
Why?
|
| Michigan | 1 | 2011 | 18 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 76 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 62 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 49 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 6 | 0.020 |
Why?
|
| Organogenesis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 116 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2010 | 25 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 15 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 77 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 301 | 0.020 |
Why?
|
| Rupture | 1 | 2010 | 109 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 476 | 0.020 |
Why?
|
| Motor Activity | 1 | 2011 | 317 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 1352 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 97 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 49 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 142 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 306 | 0.010 |
Why?
|
| Cognition | 1 | 2011 | 1250 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 1483 | 0.010 |
Why?
|